- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01986595
A Pilot Study on ALK Gene Mutations in Neuroblastoma
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
- purpose Despite the advance of modern multimodal therapy including surgery, chemotherapy, autologous stem cell transplantation, radiation therapy, and differentiation therapy, most children with NB are diagnosed with metastatic diseases and suffer from a dismal outcome. There is an unmet need for the development of novel target therapy in NB. Among all recently identified targets, ALK gene mutations have been found in approximately 10% of high-risk NB patients and are the treatment target of several promising agents that have already been tested in clinical trials, including crizotinib, which is to be available in Taiwan soon. This study aims to evaluate the prevalence of mutations and copy number aberrations of the ALK oncogene in prospective and previously treated NB patients' tumor sample (from surgical specimens) and germ-line (peripheral blood lymphocytes). The messenger ribonucleic acid(mRNA) and protein expression levels of ALK will also be analyzed. The results will be correlated with the clinical characteristics and pathological findings of this NB cohort.
- technique Prospective cases: Cryopreservation of tumor samples Retrospective cases: Archived tumor Sequencing: point mutation array-based comparative genomic hybridization(aCGH) & MLPA(multiplex ligation-dependent probe amplification):analyze copy number alterations (CNAs) compare to clinical data
- expected results The results from this study may serve as the first report on ALK gene mutations of NB in Taiwan. We anticipate that 5-15% of NB tumors carry with common ALK mutations. Genome-wide CNAs profiling by aCGH can help us to categorize the genomic types of NB patients based on published guidelines, while the presence of ALK mutation or amplification may or may not be associated with subtypes with worse outcome. Some patients may have high ALK expression level without bearing common mutations on ALK gene locus, and we may identify novel mutation points in this patient cohort. Finally, we will probably find significant prognostic value of ALK gene mutation, which may be independent from other known risk factors, such as age, stage, MYCN amplification, and genomic pattern.
Based on these results, we are able to develop standardized protocol for diagnosing ALK mutations for Taiwanese NB patients. With the development of ALK genetic testing, a phase II clinical trial of an ALK inhibitor in high-risk NB patients with relapsed or refractory disease may subsequently be conducted and may improve the treatment outcome of the patients.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Taipei, Taiwan, 100
- Reclutamento
- National Taiwan University Children Hospital
-
Contatto:
- Meng Yao Lu
- Numero di telefono: 886-9-72651499
- Email: lmy1079@gmail.com
-
Contatto:
- Charlene Chen
- Numero di telefono: 886-9-68663105
- Email: 907710@ntuh.gov.tw
-
Investigatore principale:
- Meng Yao Lu
-
Sub-investigatore:
- Chung Yi Hu
-
Sub-investigatore:
- Wen Ming Hsu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
Diagnosed by clinical criteria(one of below)
Proved or maybe as Neuroblastoma by :
- pathological section
- Bone meta with 24 hrs urine Vanillylmandelic acid(VMA)or Homovanillic acid(HVA) elevated
- CT or MRI found tumor around adrenal gland or Neuroblastic tumor
Have tumor or blood samples to analyze ALK gene:
- will operation to remove tumor or biopsy, and will preserve tumor sample;or
- after operation and have tumor sample preserved;or
- after operation without tumor sample, but agree to take blood sample to analyze ALK mutation
- Signed Inform Consent Form
Exclusion Criteria:
(1) After informed but still not consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
ALK gene mutations of NB in Taiwan
Lasso di tempo: Baseline
|
We anticipate that 5-15% of NB tumors carry with common ALK mutations.
Genome-wide CNAs profiling by aCGH can help us to categorize the genomic types of NB patients based on published guidelines, while the presence of ALK mutation or amplification may or may not be associated with subtypes with worse outcome.
Some patients may have high ALK expression level without bearing common mutations on ALK gene locus, and we may identify novel mutation points in this patient cohort.
Finally, we will probably find significant prognostic value of ALK gene mutation, which may be independent from other known risk factors, such as age, stage, MYCN amplification, and genomic pattern.
|
Baseline
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Meng Yao Lu, NTUH
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Immunoistochimica
- chinasi del linfoma anaplastico
- terapia mirata
- Neuroblastoma
- Pirosequenziamento
- genetica del cancro
- RNA and genomic DNA extraction
- complementary DNA(cDNA) preparation
- Array-comparative genomic hybridization
- Multiplex ligation-dependent probe amplification (MLPA)
- Sequencing of cDNA prepared from NB
- Quantitative real-time polymerase chain reaction(RT-PCR)
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 201306008RINB
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .